Incyte Corp (INCY) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Incyte Corp (INCY) stock forecast summary
On Oct. 16, 2026, INCY is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
Incyte Corp is a large-cap company with a market capitalization of $22.20B. It ranks number 2 by market capitalization among the 15 Services-Commercial Physical & Biological Research issuers in our coverage with a current forecast. Its Net Margin of 26.7% is the highest of the 10 peers that report one.
For INCY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 28.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 12.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, INCY included.
Follow INCY freeINCY price chart and AI forecast
How INCY ranks among 5171 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Incyte Corp (INCY) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Commercial Physical & Biological Research peers listed below that report each metric.
Valuation & Market
| Metric | INCY | Rank |
|---|---|---|
| Market Cap | $22.20B | 2/15 |
| P/E Ratio | 15.97x | – |
| P/B Ratio | 3.95x | 5/10 |
| EPS | $7.08 | – |
| Book Value/Share | $28.64 | – |
| Revenue/Share | $27.31 | – |
Profitability & Margins
| Metric | INCY | Rank |
|---|---|---|
| ROE | 25.5% | 2/9 |
| ROA | 19.5% | 2/11 |
| ROIC | 27.5% | 4/11 |
| Gross Margin | 92.5% | 1/7 |
| Operating Margin | 30.1% | 1/13 |
| Net Margin | 26.7% | 1/10 |
| EBT Margin | 33.1% | 1/13 |
| Tax Rate | 19.3% | – |
Financial Health
| Metric | INCY | Rank |
|---|---|---|
| Current Ratio | 3.68x | 4/16 |
| Quick Ratio | 3.60x | 3/6 |
| D/E Ratio | 0.31x | 8/11 |
| Financial Leverage | 1.31x | 8/10 |
| Interest Coverage | 213.7x | 2/13 |
| Working Capital | $3.99B | 1/15 |
Cash Flow
| Metric | INCY | Rank |
|---|---|---|
| Operating Cash Flow | $1.52B | 2/15 |
| OCF Growth YoY | 296.4% | 1/5 |
Operational Efficiency
| Metric | INCY | Rank |
|---|---|---|
| Asset Turnover | 0.73x | 4/8 |
| Receivables Turnover | 5.1x | 5/7 |
| Inventory Turnover | 3.5x | – |
| Fixed Assets Turnover | 7.4x | 4/9 |
| Days Sales Outstanding | 72 days | 3/7 |
| Days Inventory | 105 days | – |
| Payables Period | 207 days | 2/6 |
| Cash Conversion Cycle | -31 days | – |
Income Statement
| Metric | INCY | Rank |
|---|---|---|
| Total Revenue | $5.36B | 2/8 |
| Operating Income | $1.61B | 2/15 |
| Net Income | $1.43B | 1/12 |
| R&D Expense | $2.13B | 1/7 |
| SG&A Expense | $1.38B | 2/12 |
| Cost of Goods Sold | $403M | 3/8 |
Dividend & Shareholder Information
| Metric | INCY | Rank |
|---|---|---|
| Shares Outstanding | 196M | – |
| Net Income Growth | 6631.4% | – |
| EPS Growth | 3440.0% | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $5.48B | 74.7% of assets |
| Cash & Short-term Investments | $3.46B | 47.2% of assets |
| Accounts Receivable | $1.05B | 14.3% of assets |
| Inventory | $116M | 1.6% of assets |
| Total Liabilities | $1.72B | 23.4% of assets |
| Short-term Debt | $1.26B | 17.2% of assets |
INCY quarterly financials and insider trading
Incyte Corp (INCY) industry peers
Companies classified under the same SEC industry code as Incyte Corp (Services-Commercial Physical & Biological Research): 16 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| INCY Incyte Corp | ▶ | $22.20B |
| IQV Iqvia Holdings Inc. | ▼ | $45.37B |
| MEDP Medpace Holdings, Inc. | ▼ | $17.26B |
| CRL Charles River Laboratories International, Inc. | ▶ | $14.33B |
| ICLR Icon Plc | ▶ | $13.13B |
| ABSI Absci Corp | ▲ | $1.42B |
| OABI Omniab, Inc. | ▲ | $667M |
| NRC Nrc Health | ▲ | $446M |
| MXCT Maxcyte, Inc. | ▲ | $134M |
| ONMD Onemednet Corp | ▲ | $28M |
| VSBC Vitaspring Biomedical Co. Ltd. | ▼ | $7M |
| BIAF Bioaffinity Technologies, Inc. | ▼ | $5M |
| BUDZ Weed, Inc. | ▲ | $3M |
| ISPC Ispecimen Inc. | ▼ | $3M |
| FOXO Foxo Technologies Inc. | ▼ | $180K |
| CBIH Cannabis Bioscience International Holdings, Inc. | ▼ | N/A |
Where INCY sits on the market map
Incyte Corp (INCY) stock news
Loading...
Incyte Corp (INCY) stock forecast FAQ
What is the Incyte Corp (INCY) stock forecast?
On Oct. 16, 2026, INCY is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5171 stocks scored that day.
How accurate are Incyte Corp stock predictions?
For INCY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 28.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 12.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Incyte Corp forecasts updated?
Incyte Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Incyte Corp's industry peers?
16 issuers in our coverage, INCY included, share the SEC industry code Services-Commercial Physical & Biological Research. The largest are: Iqvia Holdings Inc. (IQV), Medpace Holdings, Inc. (MEDP), Charles River Laboratories International, Inc. (CRL), Icon Plc (ICLR), Absci Corp (ABSI), Omniab, Inc. (OABI).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.